Compare · NTLA vs ORKA
NTLA vs ORKA
Side-by-side comparison of Intellia Therapeutics Inc. (NTLA) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTLA and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NTLA carries a market cap of $6.40B.
- Over the past year, NTLA is up 60.7% and ORKA is up 568.3% - ORKA leads by 507.6 points.
- ORKA has been more active in the news (5 items in the past 4 weeks vs 3 for NTLA).
- NTLA has more recent analyst coverage (25 ratings vs 11 for ORKA).
- Company
- Intellia Therapeutics Inc.
- Oruka Therapeutics Inc.
- Price
- $16.00+0.82%
- $68.97+2.03%
- Market cap
- $6.40B
- -
- 1M return
- +2.71%
- +57.38%
- 1Y return
- +60.67%
- +568.31%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 3
- 5
- Recent ratings
- 25
- 11
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest NTLA
- Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
- SEC Form 8-K filed by Intellia Therapeutics Inc.
- The Credibility Filter Wall Street Uses to Sort Biotech Winners
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Intellia Therapeutics Inc.
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- EVP, General Counsel Basta James was granted 46,080 shares and sold $16,688 worth of shares (1,211 units at $13.78), increasing direct ownership by 40% to 156,794 units (SEC Form 4)
- President and CEO Leonard John M was granted 156,400 shares, increasing direct ownership by 15% to 1,169,739 units (SEC Form 4)
- VP, Chief Accounting Officer Dube Michael P was granted 17,250 shares, increasing direct ownership by 33% to 69,527 units (SEC Form 4)
- EVP, Chief Financial Officer Dulac Edward J Iii was granted 61,280 shares, increasing direct ownership by 61% to 160,963 units (SEC Form 4)
Latest ORKA
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Goncalves Joana
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee sold $24,780 worth of shares (600 units at $41.30), decreasing direct ownership by 0.25% to 236,984 units (SEC Form 4)